JP2011507861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507861A5 JP2011507861A5 JP2010539518A JP2010539518A JP2011507861A5 JP 2011507861 A5 JP2011507861 A5 JP 2011507861A5 JP 2010539518 A JP2010539518 A JP 2010539518A JP 2010539518 A JP2010539518 A JP 2010539518A JP 2011507861 A5 JP2011507861 A5 JP 2011507861A5
- Authority
- JP
- Japan
- Prior art keywords
- connexin
- composition
- polynucleotide
- medicament
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 58
- 108091033319 polynucleotide Proteins 0.000 claims description 58
- 239000002157 polynucleotide Substances 0.000 claims description 58
- 102000040430 polynucleotide Human genes 0.000 claims description 58
- 230000000692 anti-sense effect Effects 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 37
- 230000003176 fibrotic effect Effects 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 29
- 206010016654 Fibrosis Diseases 0.000 claims description 24
- 230000004761 fibrosis Effects 0.000 claims description 24
- 239000000816 peptidomimetic Substances 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 102000001045 Connexin 43 Human genes 0.000 claims description 16
- 108010069241 Connexin 43 Proteins 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 16
- 102000010970 Connexin Human genes 0.000 claims description 15
- 108050001175 Connexin Proteins 0.000 claims description 15
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 108091030071 RNAI Proteins 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 230000004962 physiological condition Effects 0.000 claims description 6
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000003976 gap junction Anatomy 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 4
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000006916 protein interaction Effects 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102100033299 Glia-derived nexin Human genes 0.000 claims 1
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 238000011257 definitive treatment Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US888607P | 2007-12-21 | 2007-12-21 | |
| PCT/US2008/014026 WO2009085275A2 (en) | 2007-12-21 | 2008-12-22 | Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015010581A Division JP2015083606A (ja) | 2007-12-21 | 2015-01-22 | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507861A JP2011507861A (ja) | 2011-03-10 |
| JP2011507861A5 true JP2011507861A5 (OSRAM) | 2013-04-25 |
Family
ID=40824959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539518A Withdrawn JP2011507861A (ja) | 2007-12-21 | 2008-12-22 | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 |
| JP2015010581A Pending JP2015083606A (ja) | 2007-12-21 | 2015-01-22 | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015010581A Pending JP2015083606A (ja) | 2007-12-21 | 2015-01-22 | 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110092449A1 (OSRAM) |
| EP (1) | EP2237795A2 (OSRAM) |
| JP (2) | JP2011507861A (OSRAM) |
| AU (1) | AU2008343756A1 (OSRAM) |
| CA (1) | CA2710387A1 (OSRAM) |
| WO (1) | WO2009085275A2 (OSRAM) |
| ZA (1) | ZA201005222B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006257283A1 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
| US20080076743A1 (en) | 2006-08-03 | 2008-03-27 | Nitec Pharma Ag | Delayed-Release Glucocorticoid treatment of Rheumatoid Disease |
| CN102920996A (zh) * | 2007-12-11 | 2013-02-13 | 科达治疗公司 | 受损伤口愈合的药物组合物 |
| AU2008343841A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of connexin43 for treatment of fibrotic conditions |
| JP5881698B2 (ja) * | 2010-07-19 | 2016-03-09 | ブラセルズ ベンチャーズ コーポレーションＢｒｕｓｅｌｌｓ Ｖｅｎｔｕｒｅｓ Ｃｏｒｐ． | エーテルヒドロキシエチルセルロースを含む抗微生物医療用ジェル |
| MX351881B (es) | 2012-03-01 | 2017-11-01 | Firststring Res Inc | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). |
| US10465188B2 (en) | 2014-08-22 | 2019-11-05 | Auckland Uniservices Limited | Channel modulators |
| EP3439676B1 (en) | 2016-04-04 | 2021-06-09 | Omeza LLC | Fish oil topical composition |
| CA3022763A1 (en) * | 2016-05-03 | 2017-11-09 | University Of Auckland | Novel peptides and peptidomimetics |
| WO2018199777A1 (en) | 2017-04-28 | 2018-11-01 | Auckland Uniservices Limited | Methods of treatment and novel constructs |
| EP4132555A4 (en) * | 2020-04-07 | 2023-12-27 | Xequel Bio, Inc. | COMPOSITIONS AND METHODS FOR TREATING COMPLICATIONS OF VIRAL INFECTIONS AND OTHER RESPIRATORY DISORDERS |
| AU2021364900A1 (en) | 2020-10-22 | 2023-06-08 | Xequel Bio, Inc. | Peptide formulations and ophthalmic uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4861757A (en) * | 1986-11-14 | 1989-08-29 | Institute Of Molecular Biology | Wound healing and bone regeneration using PDGF and IGF-I |
| JPH0539594Y2 (OSRAM) * | 1988-08-05 | 1993-10-07 | ||
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| US6752987B1 (en) * | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
| US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| WO1999007844A2 (en) * | 1997-08-07 | 1999-02-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for treatment of restenosis |
| WO1999029858A1 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Soluble inhibitors of vascular endothelial growth factor and use thereof |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AU776512B2 (en) * | 1999-01-27 | 2004-09-09 | David Laurence Becker | Formulations comprising antisense nucleotides to connexins |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
| JP2005509621A (ja) * | 2001-10-17 | 2005-04-14 | ユニバーシティ オブ ウェールズ カレッジ オブ メディスン | ギャップ結合ならびにｅｄｈｆ |
| EA006860B1 (ru) * | 2002-01-29 | 2006-04-28 | Уайт | Композиции и способы модулирования гемиканалов коннексина |
| US20030215424A1 (en) * | 2002-05-15 | 2003-11-20 | Seul Kyung Hwan | Method of modulating angiogenesis |
| US8809504B2 (en) * | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| DK1699924T3 (da) * | 2003-12-03 | 2019-10-21 | Ocunexus Therapeutics Inc | Connexin 43-målrettede hæmmende forbindelser og fremgangsmåder til anvendelse deraf i behandling af hornhindetraume |
| AU2006257283A1 (en) * | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
| US8247384B2 (en) * | 2006-11-15 | 2012-08-21 | Coda Therapeutics, Inc. | Methods and compositions for wound healing |
| EP2543377A1 (en) * | 2006-12-11 | 2013-01-09 | Coda Therapeutics, INC. | Anticonnexin polynucleotides as impaired wound healing compositions |
| CN102920996A (zh) * | 2007-12-11 | 2013-02-13 | 科达治疗公司 | 受损伤口愈合的药物组合物 |
-
2008
- 2008-12-22 JP JP2010539518A patent/JP2011507861A/ja not_active Withdrawn
- 2008-12-22 CA CA2710387A patent/CA2710387A1/en not_active Abandoned
- 2008-12-22 EP EP08867884A patent/EP2237795A2/en not_active Withdrawn
- 2008-12-22 US US12/809,974 patent/US20110092449A1/en not_active Abandoned
- 2008-12-22 WO PCT/US2008/014026 patent/WO2009085275A2/en not_active Ceased
- 2008-12-22 AU AU2008343756A patent/AU2008343756A1/en not_active Abandoned
-
2010
- 2010-07-21 ZA ZA2010/05222A patent/ZA201005222B/en unknown
-
2015
- 2015-01-22 JP JP2015010581A patent/JP2015083606A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507861A5 (OSRAM) | ||
| JP2011507860A5 (OSRAM) | ||
| JP2011507855A5 (OSRAM) | ||
| JP2011507858A5 (OSRAM) | ||
| JP2011506447A5 (OSRAM) | ||
| Hanon et al. | Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia | |
| RU2009122370A (ru) | Улучшенные способы и композиции для заживления ран | |
| JP2011508605A5 (OSRAM) | ||
| JP2019196370A5 (OSRAM) | ||
| US10335455B2 (en) | Method for prevention or treatment of intractable inflammatory bowel disease | |
| JP2013533858A5 (OSRAM) | ||
| CA2730789A1 (en) | Treatment of inflammatory bowel diseases with mammal beta defensins | |
| JP2016516016A5 (OSRAM) | ||
| JP2009544585A5 (OSRAM) | ||
| JPH0245425A (ja) | 脳神経障害治療用薬剤 | |
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| CN107405315A (zh) | 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 | |
| Altay et al. | Slit modulates cerebrovascular inflammation and mediates neuroprotection against global cerebral ischemia | |
| Nalamachu et al. | Lidocaine patch 5% for carpal tunnel syndrome: How it compares with injections: A pilot study. | |
| JP2016505050A5 (OSRAM) | ||
| US7935718B2 (en) | Treatment of dyskinesia | |
| KR101901001B1 (ko) | PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물 | |
| CN105451727A (zh) | 用于预防和/或治疗i型慢性创伤性脑病的方法 | |
| JP2004512360A (ja) | ５−ヒドロキシトリプタミン１ａレセプター活性増強化合物を用いる運動症状の変動の治療 | |
| CN114887063A (zh) | Pacsin1在抑制瑞芬太尼诱发的痛觉过敏中的应用 |